{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:40:23Z","timestamp":1790091623233,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recurrence of multiple myeloma is among the most challenging issues for patients and treating physicians reported after autologous stem cell transplantation. However, extramedullary involvement after chemotherapy and transplantation has been rarely reported, especially as pleural manifestations. Protein electrophoresis indicated immunoglobulin A monoclonal kappa plasma cell neoplasm in our case.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 48-year-old middle-eastern man was referred to our clinic with cough, dyspnea, fever, and left side pleural effusion. A year after chemotherapy and autologous bone marrow transplantation, the patient presented with features in favor of pleural relapse, without bone marrow involvement. Protein electrophoresis demonstrated immunoglobulin A monoclonal kappa plasma cell neoplasm in our case. The patient was effectively treated with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide with no notable adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Physicians should be aware of various presentations of multiple myeloma relapse, especially in autologous stem cell transplantation patients. Atypical and unique presentations such as the pleural involvement warrant further reporting of evidence to provide early management and treatment options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03765-9","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T01:04:57Z","timestamp":1675991097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Extramedullary relapse of Immunoglobulin A-kappa myeloma manifesting as plasmacytoma of the pleura without bone marrow involvement and following autologous bone marrow transplant: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Alireza","family":"Rezvani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Shahriarirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zeighami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"11","key":"3765_CR1","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3","volume":"85","author":"C Alexiou","year":"1999","unstructured":"Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305\u201314.","journal-title":"Cancer"},{"issue":"1","key":"3765_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1477-7819-5-123","volume":"5","author":"S-P Luh","year":"2007","unstructured":"Luh S-P, Lai Y-S, Tsai C-H, Tsao TC-Y. Extramedullary plasmacytoma (EMP): report of a case manifested as a mediastinal mass and multiple pulmonary nodules and review of literature. World J Surg Oncol. 2007;5(1):123.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"3765_CR3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/crj.12408","volume":"11","author":"A Sunnetcioglu","year":"2017","unstructured":"Sunnetcioglu A, Ekin S, Bayram I, Ekinci O, Bugday IB. Endobronchial plasmacytoma in patient with multiple myeloma. Clin Respir J. 2017;11(6):1057\u20139.","journal-title":"Clin Respir J"},{"issue":"12","key":"3765_CR4","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.bmt.1704289","volume":"32","author":"E Alyea","year":"2003","unstructured":"Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, et\u00a0al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transpl. 2003;32(12):1145\u201351.","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"3765_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","volume":"34","author":"R Zeiser","year":"2004","unstructured":"Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transpl. 2004;34(12):1057\u201365.","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"3765_CR6","first-page":"672","volume":"21","author":"A Ebrahimi","year":"2021","unstructured":"Ebrahimi A, Ahmadi H, Pourfraidon Ghasrodashti Z, Tanide N, Shahriarirad R, Erfani A, Ranjbar K, Ashkani-Esfahani S. Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: a comprehensive review. Bosn J Basic Med Sci. 2021;21(6):672\u2013701.","journal-title":"Bosn J Basic Med Sci"},{"issue":"3","key":"3765_CR7","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1111\/bjh.16770","volume":"190","author":"K-W Yeoh","year":"2020","unstructured":"Yeoh K-W, Thitsar SM, Master Z, Loh Y, Chen Y, Nagarajan C, Tin K-M, Cutter D, Mikhaeel G. Pleural plasmacytomas-the role of radiotherapy. Br J Haematol. 2020;190(3):e160\u20132.","journal-title":"Br J Haematol"},{"issue":"1","key":"3765_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0609.2008.01087.x","volume":"81","author":"J Cerny","year":"2008","unstructured":"Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence\/relapse of multiple myeloma. Eur J Haematol. 2008;81(1):65\u20139.","journal-title":"Eur J Haematol"},{"issue":"6","key":"3765_CR9","first-page":"609","volume":"87","author":"A Alegre","year":"2002","unstructured":"Alegre A, Granda A, Martinez-Chamorro C, Diaz-Mediavilla J, Martinez R, Garcia-Larana J, Lahuerta JJ, Sureda A, Blade J, de la Rubia J, et\u00a0al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica. 2002;87(6):609\u201314.","journal-title":"Haematologica"},{"issue":"5","key":"3765_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1600-0609.2005.00531.x","volume":"75","author":"E Terpos","year":"2005","unstructured":"Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol. 2005;75(5):376\u201383.","journal-title":"Eur J Haematol"},{"issue":"9","key":"3765_CR11","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1200\/JCO.1993.11.9.1832","volume":"11","author":"P Moreau","year":"1993","unstructured":"Moreau P, Bataille R, Mah\u00e9 B, Milpied N, Harousseau J. High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma. J Clin Oncol. 1993;11(9):1832\u20131832.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3765_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.1992.10.1.47","volume":"10","author":"HM Lokhorst","year":"1992","unstructured":"Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW. High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol. 1992;10(1):47\u201351.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3765_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1440-1843.2008.01319.x","volume":"13","author":"PH Feng","year":"2008","unstructured":"Feng PH, Huang CC, Wang CW, Wu YK, Tsai YH. Solitary pleural plasmacytomas manifested as a massive pleural effusion without evidence of monoclonal gammopathy. Respirology. 2008;13(5):751\u20133.","journal-title":"Respirology"},{"key":"3765_CR14","doi-asserted-by":"publisher","first-page":"bcr2015211197","DOI":"10.1136\/bcr-2015-211197","volume":"2015","author":"O Saidane","year":"2015","unstructured":"Saidane O, Slouma M, Haouet S, Abdelmoula L. Cutaneous and pleural involvement in a patient with multiple myeloma. BMJ Case Rep. 2015;2015:bcr2015211197.","journal-title":"BMJ Case Rep"},{"key":"3765_CR15","doi-asserted-by":"crossref","unstructured":"Al-Ataby H, Al-Tkrit A, Ali S, Seneviratne C, Omballi M. Pleural plasmacytomas in a patient with multiple myeloma relapse. Respir Med Case Reports 2022;2022:101777.","DOI":"10.1016\/j.rmcr.2022.101777"},{"issue":"4","key":"3765_CR16","first-page":"381","volume":"10","author":"R Or","year":"1992","unstructured":"Or R, Mehta J, Naparstek E, Okon E, Cividalli G, Slavin S. Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas. Bone Marrow Transpl. 1992;10(4):381\u20132.","journal-title":"Bone Marrow Transpl"},{"issue":"9004","key":"3765_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","volume":"347","author":"LF Verdonck","year":"1996","unstructured":"Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet. 1996;347(9004):800\u20131.","journal-title":"Lancet"},{"issue":"3","key":"3765_CR18","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3):1196\u20138.","journal-title":"Blood"},{"issue":"3","key":"3765_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000197687","volume":"32","author":"O Annibali","year":"2009","unstructured":"Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G. Relapse of IgA \u03bb multiple myeloma presenting as obstructive jaundice and abdominal pain. Oncol Res Treatment. 2009;32(3):119\u201321.","journal-title":"Oncol Res Treatment"},{"issue":"1","key":"3765_CR20","doi-asserted-by":"publisher","first-page":"7456","DOI":"10.4076\/1757-1626-2-7456","volume":"2","author":"DF Waterhouse","year":"2009","unstructured":"Waterhouse DF, Moloney GA, Gargoum FS, Hayden PS, O\u2019Gorman T. Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report. Cases J. 2009;2(1):7456.","journal-title":"Cases J"},{"issue":"24","key":"3765_CR21","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1002\/cncr.28946","volume":"120","author":"EM Boyle","year":"2014","unstructured":"Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, et\u00a0al. IgA kappa\/IgA lambda heavy\/light chain assessment in the management of patients with IgA myeloma. Cancer. 2014;120(24):3952\u20137.","journal-title":"Cancer"},{"issue":"14","key":"3765_CR22","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","volume":"21","author":"CK Lee","year":"2003","unstructured":"Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21(14):2732\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3765_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et\u00a0al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3765_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, et\u00a0al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"key":"3765_CR25","unstructured":"Oxford Myeloma Group Network site specific group (NSSG)\u2014Haematology- VDTPACE\/ DTPACE [https:\/\/nssg.oxford-haematology.org.uk]"},{"key":"3765_CR26","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Multiple Myeloma Version 2 [www.nccn.org\/patients]"},{"issue":"8","key":"3765_CR27","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ccr3.1015","volume":"5","author":"I Espanol","year":"2017","unstructured":"Espanol I, Romera M, Gutierrez-Meca MD, Garcia MDC, Tejedor A, Martinez A, Ibanez J, De Arriba F, Minguela A, Iturbe T, et\u00a0al. Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clin Case Reports. 2017;5(8):1258\u201360.","journal-title":"Clin Case Reports"},{"key":"3765_CR28","doi-asserted-by":"publisher","first-page":"2312430","DOI":"10.1155\/2018\/2312430","volume":"2018","author":"G Mele","year":"2018","unstructured":"Mele G, Pastore D. Efficacy of carfilzomib, lenalidomide, and dexamethasone for extramedullary intracranial localization of multiple myeloma. Case Reports Hematol. 2018;2018:2312430.","journal-title":"Case Reports Hematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03765-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T01:09:54Z","timestamp":1675991394000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03765-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3765"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03765-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient in our study. The purpose of this research was completely explained to the patient, and they were assured that their information would be kept confidential by the researcher. The present study was approved by the Medical Ethics Committee of the academy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}